About David B. Karpf, AB, MD:

 

David B. Karpf is Chief Medical Officer of Lumos Pharma. Dr. Karpf is an academically trained endocrinologist with over 35 years of expertise in all aspects of clinical endocrinology, including among others growth hormone deficiency, osteoporosis and metabolic bone disease, sarcopenia, as well as internal medicine.  He is also an accomplished biopharmaceutical executive. Dr. Karpf has 30 years of experience in the development of biopharmaceuticals and small molecular weight drugs in the areas of endocrinology, oncology, rare diseases, and autoimmune diseases among others, with expertise in all facets of clinical development from pre-clinical to Phase 4 and has contributed substantially to 6 NDAs. Dr. Karpf is an Adjunct Clinical Professor, Department of Medicine, Division of Endocrinology at Stanford University School of Medicine, where he has followed about 1600 patients in an endocrinology sub-specialty clinic since 1997. In his most recent executive role, Dr. Karpf was Vice President, Clinical Development for Ascendis Pharma where he was responsible for several compounds in clinical development, including TransCon GH, a long-acting growth hormone for once weekly treatment of growth hormone deficiency. Dr. Karpf previously served as Chief Medical Officer for both Virobay Inc. and Metabolex, Inc. and has held leadership positions at several other biopharmaceutical companies. Earlier in his career, Dr. Karpf held leadership positions in clinical research in endocrinology at both Roche and, prior to that, at Merck where he originally gained experience with Lumos Pharma’s oral growth hormone secretagogue, LUM-201. Dr. Karpf currently serves as a consultant or senior advisor to several biopharmaceutical companies and is Co-Chair for the Medical & Scientific Advisory Board for the American Bone Health organization.

Dr. Karpf received his AB from University of California, Berkley and his MD from University of California, San Diego. He completed his internship and residency in internal medicine and his fellowship in diabetes, endocrinology & metabolism at UCLA/Cedars-Sinai Medical Center. He completed a post-doctoral fellowship in metabolic bone disease in the Endocrine Research Unit at the VA Medical Center/UC San Francisco.